Tentative Approval Granted for Generic Rosacea Cream

In a Phase 3 head-to-head study vs. metronidazole 0.75% cream, ivermectin was more effective from Week 3
In a Phase 3 head-to-head study vs. metronidazole 0.75% cream, ivermectin was more effective from Week 3

The Food and Drug Administration (FDA) has given tentative approval to Perrigo's Ivermectin Cream, the generic version of Galderma's Soolantra cream, 1%.

Ivermectin cream is a semi-synthetic derivative isolated from the fermentation of Streptomyces avermitilis that belongs to the avermectin family of macrocyclic lactones. It is indicated to treat inflammatory lesions of rosacea.  

Related Articles

Ivermectin was initially approved by the FDA in December 2014. In a Phase 3 head-to-head study vs metronidazole 0.75% cream, ivermectin cream proved more effective from Week 3 onward.

Perrigo reached a settlement with Galderma Laboratories and Nestle Skin Health concerning this generic version of Soolantra. 

For more information call (866) 634-9120 or visit Perrigo.com